Key Takeaways
Life Biosciences dosed the first patient in the first-in-human trial of ER-100, which the company calls the first cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials.
NewLimit, the longevity startup co-founded by Coinbase CEO Brian Armstrong, raised a $435 million Series C to fund its own first human trial of a cell-age reprogramming therapy.
Partial epigenetic reprogramming uses the same OCT4, SOX2, and KLF4 factors behind a Nobel Prize, resetting a cell's biological age without erasing what the cell is.
Two Boston-area longevity companies moved cellular rejuvenation from mouse studies into human patients this year, a line the field has chased for a decade.
Life Biosciences, co-founded by Harvard geneticist David Sinclair, said on June 9 that it dosed the first patient in a Phase 1 trial of ER-100, a therapy that uses partial epigenetic reprogramming to push aged cells back toward a younger state. The company calls it the first cellular rejuvenation therapy of its kind to reach human testing. The trial targets two optic-nerve conditions, open-angle glaucoma and a sudden vision-loss disorder called NAION, and in monkeys with optic-nerve injury a single injection improved visual function.
The method borrows the three factors, OCT4, SOX2, and KLF4, behind Shinya Yamanaka's Nobel-winning work turning adult cells back into stem cells. The trick is stopping partway, resetting a cell's epigenetic age without erasing what it is, so a nerve cell stays a nerve cell and simply behaves younger.
A week earlier, NewLimit, the longevity startup co-founded by Coinbase chief executive Brian Armstrong, raised $435 million to fund its own first human trial, after a lead compound for liver cells arrived years ahead of the company's schedule.
The most notable part of this is that making a cell younger now has a patient attached to it, not just a mouse. WYDE has followed the same frontier from other angles, from Conception's claim to have grown the first human eggs from stem cells to the University of Minnesota team that built SpudCell, a synthetic cell with a full life cycle. The open question is not only whether reprogramming works in people, but who reaches it first if it does. Worth watching.
People Also Ask
What is cellular rejuvenation therapy?
Cellular rejuvenation therapy uses partial epigenetic reprogramming to reset the biological age of cells toward a younger state while keeping their identity, aiming to restore function lost to aging or injury.
What is ER-100 and what does it treat?
ER-100 is Life Biosciences' partial epigenetic reprogramming therapy, now in a Phase 1 trial for two optic-nerve conditions, open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, known as NAION.
Who is behind NewLimit?
NewLimit is a longevity biotech co-founded by Coinbase CEO Brian Armstrong. It raised a $435 million Series C in June 2026 to fund its first human trial of a cell-age reprogramming therapy.
Can partial epigenetic reprogramming reverse aging in people?
No one knows yet. Both programs start with small Phase 1 studies focused on safety in specific diseases, and any broader claim about slowing or reversing aging is still years of testing away.
Sources: Life Biosciences via GlobeNewswire, STAT News.